Patient Square Capital

LXE Hearing is a company focused on championing hearing wellness for everyone, everywhere. The company's mission is to revolutionize hearing wellness through innovation, ensuring access to affordable, life-enhancing solutions.

Patterson Companies, Inc. is a leading distributor of dental and animal health products, operating primarily in the United States, with additional markets in the United Kingdom and Canada. The company is structured into three segments: Dental, Animal Health, and Corporate. The Dental segment supplies a wide range of consumable products, dental equipment, and technology solutions, alongside various services such as maintenance and financing. The Animal Health segment focuses on distributing pharmaceuticals, vaccines, diagnostics, and nutritional products, while also offering private label items under established brands. The Corporate segment provides customer financing services and miscellaneous products. Patterson Companies serves a diverse clientele that includes dentists, laboratories, veterinarians, and other healthcare professionals. Founded in 1877 and headquartered in Saint Paul, Minnesota, the company was originally known as Patterson Dental Company before rebranding in 2004.

CorroHealth is a company that focuses on healthcare analytics and technology solutions aimed at enhancing revenue cycle management for healthcare systems. By using advanced analytics and proprietary artificial intelligence, CorroHealth seeks to improve the financial performance of hospitals and healthcare facilities. The company also offers reimbursement cycle tracking services, addressing regulatory and compliance challenges while integrating revenue cycle technologies. This approach not only alleviates burdens on physicians but also aims to improve financial outcomes for both healthcare providers and payers.

Nuclera is a biotechnology company specializing in an automated protein prototyping system aimed at enhancing drug discovery processes. Its eProtein Discovery system enables researchers to rapidly produce and test high-quality, soluble, and active proteins, significantly accelerating protein projects. By integrating technology such as cell-free protein synthesis and digital microfluidics, Nuclera provides a high-throughput platform for automated protein access. This innovative approach allows scientists to obtain reliable proteins within a short timeframe, facilitating faster progress in their research and contributing to more efficient drug development efforts.

GondolaBio researches, develops and manufactures pharmaceutical products.

NanoString Technologies, Inc. is a provider of life science tools focused on translational research and molecular diagnostics, headquartered in Seattle, Washington. Established in 2003, the company utilizes a unique digital molecular barcoding technology to create a range of products that facilitate gene expression analysis, microRNA studies, and copy number variation detection. Key offerings include the nCounter Analysis System, which consists of the nCounter MAX and FLEX systems, and the nCounter SPRINT Profiler, all designed for automated sample processing and data collection. The nSolver Analysis Software aids researchers in data normalization and analysis. Additionally, NanoString provides various custom CodeSets and panels tailored for specific applications, including cancer profiling and autoimmune disease research. The company is advancing the field of spatial genomics with its GeoMx Digital Spatial Profiler system and is developing the Hyb & Seq molecular profiling system for gene sequence analysis. NanoString collaborates with several pharmaceutical companies and research institutions to enhance its product offerings and expand its impact in the scientific community.

Liquidia Technologies is a late-stage clinical biopharmaceutical company based in the United States, dedicated to developing and commercializing innovative therapeutics. Utilizing its proprietary PRINT technology, a particle engineering platform, Liquidia produces uniform drug particles aimed at enhancing the safety and efficacy of various therapies. The company is advancing two key product candidates: LIQ861, intended for the treatment of pulmonary arterial hypertension, and LIQ865, designed for managing local post-operative pain. Additionally, Liquidia collaborates with leading pharmaceutical firms to leverage its PRINT technology across multiple therapeutic areas, molecule types, and administration routes, addressing unmet patient needs, particularly in the realm of pulmonary hypertension.

Apollo Therapeutics is a biopharmaceutical company based in Cambridge, United Kingdom, that collaborates with three leading UK universities—Imperial College London, University College London, and the University of Cambridge—and three major pharmaceutical companies. The company focuses on translating groundbreaking medical research into effective therapeutics, facilitating the development of pre-clinical and clinical-stage assets. Apollo Therapeutics manages a venture capital fund that provides financial and technical support for innovative projects sourced from top British academic research, with a particular emphasis on areas such as oncology, major inflammatory disorders, and rare diseases. By leveraging its experienced team of industry scientists, Apollo aims to optimize therapeutic delivery and enhance patient treatments and outcomes, establishing a strong link between academia and the pharmaceutical industry to foster impactful medical advancements.

Syneos Health, LLC is a global contract research organization that specializes in clinical research and consulting services for the biopharmaceutical and medical device industries. The company provides a comprehensive range of services, including phase II to IV clinical development, biometrics, data operations, biostatistics, medical writing, project management, safety monitoring, and global regulatory consulting. Syneos Health connects customers, clinical research sites, and patients to expedite the introduction of new medicines to the market. With a workforce of approximately 24,000 professionals, Syneos Health operates in over 110 countries, leveraging advanced technologies and insights to enhance customer performance. Founded in 1985 and based in Raleigh, North Carolina, the organization was formerly known as INC Research, LLC, before rebranding in 2018.

Apollo Therapeutics is a biopharmaceutical company based in Cambridge, United Kingdom, that collaborates with three leading UK universities—Imperial College London, University College London, and the University of Cambridge—and three major pharmaceutical companies. The company focuses on translating groundbreaking medical research into effective therapeutics, facilitating the development of pre-clinical and clinical-stage assets. Apollo Therapeutics manages a venture capital fund that provides financial and technical support for innovative projects sourced from top British academic research, with a particular emphasis on areas such as oncology, major inflammatory disorders, and rare diseases. By leveraging its experienced team of industry scientists, Apollo aims to optimize therapeutic delivery and enhance patient treatments and outcomes, establishing a strong link between academia and the pharmaceutical industry to foster impactful medical advancements.

Kriya Therapeutics, Inc. is a gene therapy company focused on creating innovative treatments for chronic diseases. Founded in 2019 and headquartered in Palo Alto, California, with an additional office in Durham, North Carolina, Kriya Therapeutics has developed a fully integrated platform that consolidates the essential infrastructure and technology for the engineering, manufacturing, characterization, and clinical development of gene therapies. The company utilizes a vector design platform that enhances its ability to design new constructs, modify sequences, and analyze data, ultimately enabling physicians to reduce immunogenicity and enhance tissue specificity in their therapeutic approaches.

Elevage Medical Technologies is a company focused on advancing the development of medical devices and therapeutic solutions aimed at improving health outcomes and quality of life for patients. By providing both financial support and strategic guidance, Elevage assists life science and medical device companies in enhancing their therapeutic pipelines. The company's commitment lies in fostering innovation within the healthcare sector, enabling these companies to develop and accelerate novel therapies. Through its efforts, Elevage seeks to transform healthcare and deliver meaningful improvements in patient health.

Eargo, Inc. is a consumer-focused medical device company based in San Jose, California, specializing in the design and development of hearing aids for individuals with hearing loss. Founded in 2010, Eargo offers a range of rechargeable hearing aids that can be controlled via smartphone, along with online hearing screenings and virtual support services to eliminate the need for in-person visits. The company's innovative approach aims to address common barriers to hearing aid adoption, such as social stigma, accessibility, and cost, thereby enhancing the quality of life for its users. Eargo sells its products directly to consumers through online platforms, positioning itself as a modern alternative to traditional hearing aid solutions.

Resolve BioSciences GmbH, founded in 2016 and based in Monheim am Rhein, Germany, specializes in spatial multiomics analysis platforms that enhance the understanding of single-cell spatial biology. The company's technology offers a comprehensive, high-resolution view of subcellular gene expression activities, which is crucial for advancements in various fields such as oncology, neuroscience, and infectious diseases. Resolve BioSciences provides a range of services and expertise in bioinformatics, imaging, genomics, transcriptomics, histology, and pathology, among other areas. This innovative approach supports researchers in their efforts to explore complex biological systems and improve outcomes in health and agriculture.

Hanger, Inc. is a leading health care company based in Austin, specializing in orthotic and prosthetic (O&P) services and products. It operates primarily through two segments: Patient Care and Products and Services. The Patient Care segment, which is the main revenue driver, includes Hanger Clinic, which focuses on the design, fabrication, and delivery of custom O&P devices across more than 700 clinics. Additionally, the Products and Services segment provides distribution and therapeutic solutions to various businesses. Hanger, Inc. is recognized for its commitment to clinical excellence and patient-centered care, leveraging advanced technologies to enhance or restore the physical capabilities of individuals with disabilities or injuries.

Eargo, Inc. is a consumer-focused medical device company based in San Jose, California, specializing in the design and development of hearing aids for individuals with hearing loss. Founded in 2010, Eargo offers a range of rechargeable hearing aids that can be controlled via smartphone, along with online hearing screenings and virtual support services to eliminate the need for in-person visits. The company's innovative approach aims to address common barriers to hearing aid adoption, such as social stigma, accessibility, and cost, thereby enhancing the quality of life for its users. Eargo sells its products directly to consumers through online platforms, positioning itself as a modern alternative to traditional hearing aid solutions.

Alladapt Immunotherapeutics, Inc. is a biopharmaceutical company focused on developing therapeutics for food allergies. Founded in 2018 and based in Menlo Park, California, the company is advancing its lead program, ADP101, which aims to provide a broad-spectrum oral immunotherapy treatment. This innovative drug targets the mitigation, treatment, and prevention of food allergies caused by single or multiple proteins from a wide range of common allergens. Through its research and development efforts, Alladapt Immunotherapeutics seeks to enable healthcare providers to effectively address the challenges faced by patients with various food allergies.

Kriya Therapeutics, Inc. is a gene therapy company focused on creating innovative treatments for chronic diseases. Founded in 2019 and headquartered in Palo Alto, California, with an additional office in Durham, North Carolina, Kriya Therapeutics has developed a fully integrated platform that consolidates the essential infrastructure and technology for the engineering, manufacturing, characterization, and clinical development of gene therapies. The company utilizes a vector design platform that enhances its ability to design new constructs, modify sequences, and analyze data, ultimately enabling physicians to reduce immunogenicity and enhance tissue specificity in their therapeutic approaches.

Enavate Sciences, established in 2022 and based in New York, is a private equity firm focused on the life sciences sector. The firm specializes in investing in innovative therapeutic and enabling technology companies, targeting both pre-clinical and clinical-stage enterprises. Enavate Sciences is dedicated to fostering the strategic growth of its portfolio companies, aiming to advance developments in therapeutic and technological solutions within the life sciences industry.

Access TeleCare is a provider of acute care telemedicine services designed for hospitals, health systems, post-acute providers, and physician networks. The company specializes in a range of telehealth services, including telecardiology, teleneurology, telepsychiatry, telepulmonology, telehospitalists, teleinfectious disease, and telematernal fetal medicine. By leveraging advanced technology, Access TeleCare facilitates virtual patient care, allowing healthcare organizations to develop and sustain telemedicine programs across various clinical specialties. The company's model supports healthcare providers in enhancing patient access to specialized care while maintaining quality and efficiency in service delivery.

Roivant Sciences is a biopharmaceutical company dedicated to advancing the development of innovative late-stage drug candidates and enhancing healthcare delivery. The company aims to expedite the process of bringing new medicines to patients while reducing associated costs, thereby benefiting the healthcare system. Roivant achieves this by creating specialized entities known as "Vants," which are agile biotech and healthcare technology companies that leverage unique talent sourcing and incentive alignment strategies. In addition to its focus on biopharmaceuticals, Roivant incubates discovery-stage companies and health technology startups that complement its core business. Among its commercial-stage drug candidates is VTAMA, a treatment for plaque psoriasis in adults, along with several other candidates, including Batoclimab, IMVT-1402, Brepocitinib, and Namilumab, which are at various stages of development.

Summit Behavioral Healthcare, LLC operates a network of behavioral health centers focused on addiction treatment and related services. Founded in 2013 and based in Brentwood, Tennessee, the company has expanded its reach to multiple states, including California, Missouri, Georgia, Pennsylvania, Louisiana, South Carolina, and Texas. Summit BHC provides a comprehensive range of programs, such as residential chemical dependency treatment, detoxification, partial hospitalization, and intensive outpatient services. The organization is dedicated to supporting adults and families dealing with addiction to alcohol and other drugs, addressing the underlying stressors contributing to substance use. By offering evidence-based treatment options in a supportive environment, Summit aims to facilitate recovery and promote long-term well-being for its patients.

Kriya Therapeutics, Inc. is a gene therapy company focused on creating innovative treatments for chronic diseases. Founded in 2019 and headquartered in Palo Alto, California, with an additional office in Durham, North Carolina, Kriya Therapeutics has developed a fully integrated platform that consolidates the essential infrastructure and technology for the engineering, manufacturing, characterization, and clinical development of gene therapies. The company utilizes a vector design platform that enhances its ability to design new constructs, modify sequences, and analyze data, ultimately enabling physicians to reduce immunogenicity and enhance tissue specificity in their therapeutic approaches.

Apollo Therapeutics is a biopharmaceutical company based in Cambridge, United Kingdom, that collaborates with three leading UK universities—Imperial College London, University College London, and the University of Cambridge—and three major pharmaceutical companies. The company focuses on translating groundbreaking medical research into effective therapeutics, facilitating the development of pre-clinical and clinical-stage assets. Apollo Therapeutics manages a venture capital fund that provides financial and technical support for innovative projects sourced from top British academic research, with a particular emphasis on areas such as oncology, major inflammatory disorders, and rare diseases. By leveraging its experienced team of industry scientists, Apollo aims to optimize therapeutic delivery and enhance patient treatments and outcomes, establishing a strong link between academia and the pharmaceutical industry to foster impactful medical advancements.